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Abstract 
Intraoral granulocytic sarcoma is an unusual manifestation of chronic or acute leukemia. The oral manifestations 
often involve enlargements of the gingival and mucosal tissue from direct leukemic cell infiltration. Only 38 cases 
have been reported in scientific literature to date. We present the case of a 47 year-old female who was diagnosed 
with chronic myeloid leukemia (CML) in December 2006. She was referred to a dentist for further evaluation, 
revealing generalized gingival overgrowth as well as periodontal, apical disease, and bleeding of the gums. An 
oral biopsy was performed and histological features revealed immature blast-like cells.
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Introduction
Granulocytic sarcoma (GS), also known as extramedul-
lary myeloid tumor or chloroma, is a rare solid tumor 
composed of immature cells of the granulocyte series, 
which occur in an extramedullary site (1). GS is most 
frequently found in acute and chronic leukemia patients 
and can precede acute myeloid leukemia and the blast 
crisis stage of chronic myeloid leukemia. This tumor 
most often occurs in the subperiosteal bone structure 
and soft tissue, but can also be found in the skin, lymph 
nodes, bone, orbit and eye, bronchi, pericardium, peri-
toneum, gastrointestinal tract, kidney, reproductive or-
gans, breast, and bladder.  Although oral manifestations 
of AML are common and often involve enlargements 
of the gingiva and mucosal tissue from direct leukemic 
cell infiltration, involvement of GS is, however, rare and 
only 38 cases have been reported in scientific literature 
to date (1,2).
Therefore, this paper presents a rare case of intraoral 
granulocytic sarcoma in the upper and lower jaws du-
ring a blastic crisis stage of chronic myeloid leukemia 
with the aim of providing clinicians with more know-
ledge about the pathology in order to improve the ma-
nagement of affected patients.
Case Report
A 47 year-old female patient was suffering from chronic 
myeloid leukemia (CML) Ph+, diagnosed in December 
2006 by bone marrow biopsy and myelogram. She was 
referred to a dentist for further evaluation in August 
2007. A physical examination revealed generalized 
gingival overgrowth (Fig. 1), periodontal and apical 
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diseases, and bleeding gums. The patient was given 
clinical treatment to control dental and gingival infec-
tious foci and an incisional biopsy of the oral mass was 
performed under local anesthesia. An histological ex-
amination, using hematoxylin and eosin, showed a dif-
fuse infiltrate with a monomorphous population of im-
mature blast-like cells. The cells were large in size and 
round-to-oval in shape, and the cytoplasm was mild to 
moderately basophilic without granules. Also, the cells 
had an increased nuclear-to-cytoplasmatic ratio and nu-
clei were round with fine chromatin. Rare mitotic figu-
res were observed but eosinophilic myelocytes were not 
seen. Connective tissue showed a partial substitution by 
leukemic mass with immature cells (Fig. 2–A, B and 
C). The specimen was immunohistochemically posi-
tive for lysozyme (Fig. 2–D), myeloperoxidase (MPO) 
(Fig. 2-E) and TdT (terminal deoxynucleotidyl trans-
ferase (Fig. 2-F). No reactivity to lymphoid antigens, 
such as CD3 and CD20, was observed (data not shown). 
Three months after being diagnosed with GS, the pa-
tient died. 
Discussion
Intraoral GS is a rare manifestation of chronic or acute 
leukemia and can involve any site of the oral cavity. 
There are 38  reported cases of intraoral GS in the 
PubMed database between 1970 and 2009 (1,3,4). In the 
vast majority of these reports, GS has occurred in pa-
tients with diagnosed leukemia, although in a few cases 
the oral cavity was the first site of underlying disease 
(5). In summary, three out of 38 cases of intra oral GS 
occurred in CML patients and just one involved upper 
and lower jaws. This report presents an additional case 
that involved the upper and lower jaw and which was 
secondary to a CML blastic crisis. Although the diag-
nosis of CML had been previously established, the oral 
cavity biopsy was performed to confirm the diagnosis 
of the tumor. 
Oral manifestation of malignant myeloid precursors is 
very rare, and it is important to establish a differential 
diagnosis with malignant lymphoid tumors when they 
present as the primary manifestation. Menasce et al. 
suggested in 1999 (6), an immunohistochemistry panel 
to exclude malignant lymphoma from extra-medullar 
myelogenous infiltration (EMMI), including myeloid 
markers (myeloperoxidase and lysozyme) together with 
other B- and T- lineage markers. Although the differen-
tial diagnosis was performed using lymphoid markers 
(CD3 and CD20), the history of concurrent leukemia led 
to the diagnosis of oral GS. In addition, in this case, 
B-cell and T-cell lymphoma were excluded by negative 
stains for CD3 and CD20. 
This diagnosis was confirmed by positivity for myeloid 
markers (myeloperoxidase, lysozyme and TdT). The 
sensitivity of immunohistochemistry for identifying the 
Fig. 1. A and B: Clinical mani-
festations in oral mucosa.
Fig. 2. A. Diffuse infiltrate with monomorphous immature-like cells 
(hematoxilin and eosin staining, 40x). B: Partial substitution of con-
nective tissue by leukemic cells (100x). C: Infiltrate cells with large 
size and round-to-oval shape and mild to moderate basophilic cyto-
plasm without granules (200x).  D,E: Tumor cells showed strongly 
positive reaction to lysozyme  and myeloperoxidase (MPO) stain 
(40x) F: Neoplastic cells are positive for TdT (terminal deoxynucle-
otidyl transferase).
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morphology of neoplastic cells was studied by Alexiev 
in 2007 (7), who concluded that CD43 and lysozyme, as 
well as MPO and CD117, were the most sensitive mark-
ers for large number of neoplastic cells and myeloid dif-
ferentiation, respectively. In this study, lysozyme and 
MPO were used to ensure consistent positivity for these 
markers, which reflected the degree of neoplastic and 
myeloid differentiation of the cells.  MPO is localized 
in the primary granules of myeloid cells and is synthe-
sized early in the differentiation, thereby serving as an 
important marker for myeloid lineage (8). MPO allows 
one to distinguish between AML and acute lymphob-
lastic leukemia in which blast cells are negative to this 
marker (9-11). The use of a large immunohistochem-
istry panel has been suggested by most authors when 
making a diffe-rential diagnosis between GS and lym-
phoid as well as other myeloid tumors (6-8). However, a 
concise immunohistochemistry panel including CD20, 
CD43, CD68, and MPO can successfully identify the 
majority of extramedullary myeloid tumors (12). In line 
with clinical information that exists on the blast crisis 
stage of CML, a concise immunohistochemistry panel 
was carried out to further diagnose GS in the oral mu-
cosa. These findings showed that the strong specificity 
of myeloid mar-kers (Tdt, lizosyme and MPO) and the 
lack of expression of lymphoid markers CD3 and CD20 
seem to be sufficient to distinguish GS from lymphoid 
tumors. 
GS rarely precedes the onset of AML, and when it oc-
curs, data from scientific literature suggest that chemo-
therapy at this stage may delay the onset of AML by 36 
months compared with 6 months for non-chemotherapy 
patients (13). The oral mucosa may be an indication of 
such local events, and therefore a correct clinical and 
histological early diagnosis of GS is important in order 
to initiate early chemotherapy.
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